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A B S T R A C T
Background: In primary biliary cirrhosis (PBC) and primary
sclerosing cholangitis (PSC) significant therapeutic
effects of glucocorticoids have not been documented. The
most important clinical problem in patients with these
diseases is fatigue, which is occasionally invalidating.
Abnormalities in the hypothalamo-pituitary-adrenal axis
have been suggested as a cause of fatigue. Most effects of
glucocorticoids are mediated by the glucocorticoid receptor
(hGR ). Recently a causative role for a splicing variant of
the glucocorticoid receptor (hGR ) has been proposed
in glucocorticoid resistance in asthma and ulcerative
colitis, whereas another splicing variant (hGR P) might
be associated with glucocorticoid-resistant haematological
malignancies. The aims of the present pilot study were to
assess abnormalities in glucocorticoid receptor expression
and to relate these abnormalities to the development of
fatigue and to disease activity and severity in autoimmune
cholestatic liver disease. 
Methods: Five fatigued and five nonfatigued patients with
PBC or PSC were included, and the results were compared
with healthy controls. 
Results: The expression of hGR P was not different from
controls, but hGR  mRNA was significantly increased
(p=0.02) and hGR  mRNA decreased (p=0.015). There
were no significant differences between fatigued and
nonfatigued patients. A significant negative correlation
between the serum activity of alkaline phosphatase and
hGR  and hGR P mRNA was found. 
Conclusion: Although there was no relation with fatigue,
abnormalities in hGR expression appear to occur in patients
with these diseases, and may play a role in its pathophysi-
ology and the poor response to glucocorticoid treatment.
I N T R O D U C T I O N
Primary biliary cirrhosis (PBC) and primary sclerosing
cholangitis (PSC) are chronic cholestatic liver diseases
with a relatively favourable prognosis for most patients.1,2
Clinically, the most frequent and occasionally invalidating
symptom is fatigue. In PBC, the prevalence of fatigue of
any severity is around 85%. Although fatigue has not
been studied as extensively in PSC, it appears to occur
with comparable frequency in patients with this disease.3-5
There is no correlation with the biochemical or histological
severity of the disease.6 Although several studies have
attempted to elucidate the pathophysiological mechanisms
causing fatigue in cholestatic liver diseases, these have so
far remained unknown.7 In addition, there have been no
reports of drugs or other treatment modalities with a
beneficial effect on fatigue. Although the widely used
drug ursodeoxycholic acid improves the biochemical
abnormalities in these diseases, it usually has no effect
on fatigue.6,8
Since fatigue is the most important and still an untreatable
problem in many patients with these diseases, attempting
to elucidate the mechanisms leading to fatigue may be an
important step in finding an effective treatment. One of the
possible mechanisms is dysfunction of the hypothalamo-
pituitary-adrenal axis, a role of which has been implicated
in the pathophysiology of chronic fatigue.9 Since the
actions of glucocorticoids are mediated by the intracellular
glucocorticoid receptor, this receptor has been studied for
defects associated with abnormalities in glucocorticoid
function.10 Previously, three splicing variants of the gluco-
corticoid receptor have been described. The hGR  is the
active form of the hGR, while hGR  and hGR P are
derived by alternative splicing of the original transcript.11,12
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The hGR P has been reported to increase the activity of
hGR  in several cell lines, and it has been suggested
that it may be related to glucocorticoid resistance in
haematological malignancies.12,13 Increased expression of
the -variant of the glucocorticoid receptor (hGR), which
is formed by alternative splicing of the hGR gene-transcript
and is present in normal human tissues, was associated
with glucocorticoid resistance in asthma and ulcerative
colitis.14-19 Although the mechanism causing the increased
expression of hGR  is partially unclear, it has been
repeatedly found that induction by proinflammatory
cytokines may be involved.20-22 This finding led to the
hypothesis that glucocorticoid resistance might be the
result of an abnormal inflammatory response.23 Since an
increased production of inflammatory cytokines has also
been observed in cholestatic liver diseases, the expression
of hGR  might be increased in these diseases.24-27 In
addition, glucocorticoid treatment is not recommended
in these diseases since studies assessing the efficacy of
glucocorticoids found only modest effects, suggesting
that relative glucocorticoid resistance might exist.28,29 No
studies attempting to find a relation between expression
of hGR  in chronic inflammatory diseases and fatigue
have been reported. We hypothesised that increased
expression of hGR  might not only be present in these
diseases, but that it might also be associated with fatigue.
The present study was performed to determine whether
levels of the variants of the hGR in peripheral blood
mononuclear leukocytes are different from controls in
these cholestatic liver diseases, as well as to assess the
relation between hGR expression and fatigue.
P A T I E N T S  A N D  M E T H O D S
In the present pilot study five patients with a diagnosis of
PBC or PSC without fatigue and five patients with chronic
and significant fatigue were included. Sex, age and dose
of ursodeoxycholic acid were recorded. Serum activity of
aspartate aminotransferase, alkaline phosphatase, total
serum bilirubin and total immunoglobulin M were
measured as markers of disease severity and activity.
Fatigue severity was quantified using a visual analogue
scale (VAS) and the Fisk fatigue severity scale (FFSS).30
The FFSS includes social, cognitive and physical
domains, in which these aspects of fatigue are quantified.
It has been validated for use in primary biliary cirrhosis.31
A visual analogue scale was used in order to quantify pruritus.
Informed consent was obtained from each patient and the
study was approved by the institutional review committee.
Laboratory techniques
Blood samples were obtained from a group of 12 healthy
controls and the 10 patients. To isolate peripheral blood
mononuclear leukocytes, the samples were diluted twofold
with saline and layered over Ficoll-Hypaque (Pharmacia,
Uppsala, Sweden).
Density gradient centrifugation was performed at 1410
rpm for 30 minutes at room temperature. The peripheral
blood mononuclear leukocytes enriched interphase was
isolated and washed twice with saline and the final pellet
was suspended with saline. RNA was immediately isolated
using a high-resolution RNA isolation kit (Roche Diagnostics
GmbH, Mannheim, Germany). After RNA elution in 55 l
elution buffer the concentration of isolated RNA was
measured using a Ribo-Green RNA Quantitation Reagent
and Kit (Brunschwig Chemie, Amsterdam, the Netherlands).
Using 5 M Random Hexamers and 200 nM Oligo-dt-
primers in a first-strand cDNA synthesis kit (Applied
Biosystems, Foster City, USA), 800 ng of total RNA was
used for reverse transcription reaction of 50 l. Reactions
lacking reverse transcriptase were also run to generate
controls for assessment of genomic DNA contamination.
For the different hGR splice variants 2 l of the resulting
cDNA were amplified in real-time PCR assays on the ABI
Prism 7700 (ABS, Nieuwerkerk a/d IJssel, the Netherlands)
in a total volume of 25 l containing 300 pmol of each primer
and 200 pmol probe in a qPCR-core kit (Eurogentec, Liege,
Belgium). After an initial denaturation at 95 °C for ten
minutes, PCR was performed for 42 cycles of denaturation
for 15 seconds and annealing for one minute at 60 °C.
To detect the expression of the hGR splice variants we
used the same upstream primer: 5’-TGT TTT GCT CCT
GAT CTG A-3’, encoding part of exon 6, as well as the
same taqman probe: 5’-FAM-TGA CTC TAC CCT GCA
TGT ACG AC-TAMRA-3’, encoding part of exon 7, for all
isoforms. To discriminate hGR ,  and P from each other
we used specific downstream primers. The sequences of
these reverse primers are as follows: rev-: 5’-TCG GGG
AAT TCA ATA CTC A-3’, encoding part of exon 9, rev-:
5’TGA GCG CCA AGA TTG T-3’, encoding part of exon
9, and rev-P: 5’-GTT TCT GCC ATA CCT ATT TG-3’,
encoding part of intron 7. The expression levels were
determined relatively by using the expression of the HPRT
housekeeping gene (hyoxantine phosphoribosyltransferase
with the forward primer (500 pmol): 5’CAC TGG CAA
AAC AAT GCA GAC T-3’, the reverse primer (500 pmol):
5’-GTC TGG CTT ATA TCC AAC ACT TCG T-3’, and the
probe (200 pmol): 5’FAM-CAA GCT TGC GAC CTT
GAC CAT CTT TGG A-TAMRA-3’.
Because of the supposed interactions between the hGR 
and hGR P variants with the active hGR  variant, we
calculated the hGR /hGR  and the hGR /hGR P ratios.
Statistical analysis
Differences in the expression of variants of hGR mRNA
between patients and controls, and differences between
fatigued and nonfatigued patients were tested using
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Mann-Whitney’s nonparametric test for independent
samples. Correlations between the severity of fatigue and
laboratory values and the hGR expression were tested using
Pearson’s correlation method. Logarithmic transformations
of laboratory values were used. All statistical tests were
performed using SPSS version 9.0.
R E S U L T S
Ten patients with cholestatic liver disease were included
in the study, five of whom complained about fatigue.
Seven patients had a diagnosis of PBC and three had been
diagnosed with PSC. A summary of patient characteristics
is shown in table 1.
To assess differences in hGR mRNA levels related to the
presence of the disease, we compared the levels of the
three variants of the hGR, as well as the hGR /hGR P
ratio and the hGR /hGR  ratio with the levels in a
group of healthy controls. These tests resulted in non-
significant p values for hGR P and p values of 0.015 for
the hGR  variant and 0.02 for the hGR  variant, with
decreased numbers of hGR  and increased numbers of
hGR  mRNA in patients vs controls. In addition, the
hGR /hGR  ratio was significantly decreased in
patients (table 2).
Tests for differences between fatigued and nonfatigued
patients were performed, and resulted in p values of
0.99 for hGR , 0.65 for hGR  and 0.28 for hGR P.
No significant correlations were found between GR
mRNA levels and quantified fatigue (table 3).
Finally, correlation testing was performed to find associations
between the GR variants and the markers of disease
severity and activity. A significant, negative correlation was
found between the serum alkaline phosphatase activity
and hGR  and hGR P, as well as total hGR mRNA. For
the levels of aspartate aminotransferase, bilirubin and
immunoglobulin M, no significant correlations were
found (table 4). Figure 1 illustrates this relation between
alkaline phosphatase and total hGR mRNA.
D I S C U S S I O N
In the present study we found increased levels of hGR 
mRNA and decreased levels of hGR  mRNA in patients
with cholestatic liver disease compared with healthy controls.
As a result, the hGR /hGR  ratio was significantly
decreased. In addition, there was a significant inverse
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Table 1 
Patient characteristics
ALL PATIENTS FATIGUE + FATIGUE -
Male/female 4 / 6 3 / 2 1 / 4
PSC/PBC 3 / 7 3 / 2 0 / 5
Age 58 (40-76) 53 (40-62) 64 (55-76)
UDCA dose (mg/day) 900 (0-1200) 900 (0-1200) 900 (600-1200)
Bilirubin (mol/l) 15.5 (7-89) 15 (10-89) 16 (7-43)
Alkaline phosphatase (U/l) 171 (72-441) 188 (122-441) 154 (72-427)
Aspartate aminotransferase (U/l) 40 (27-241) 39 (27-241) 40 (30-65)
Immunoglobulin M (g/l) 1.8 (1.1-3.9) 2.8 (1.2-3.9) 1.6 (1.1-2.4)
Visual analogue score for pruritus (cm) 0.6 (0-3.3) 0.9 (0-2.5) 0 (0-3.3)
Visual analogue score for fatigue (cm) 3.15 (0-9.3) 6.2 (4.3-9.3) 0 (0-2.0)
FFSS physical domain 9 (1-32) 24 (10-32) 1 (1-8)
FFSS cognitive domain 4.5 (0-21) 7 (4-21) 2 (0-5)
FFSS social domain 7.5 (0-42) 31 (9-42) 3 (0-6)
Values are medium (range). PSC = primary sclerosing cholangitis, PBC = primary biliary cirrhosis, FFSS = Fisk fatigue severity scale.
Table 2 
Glucocorticoid receptor mRNA levels, number of copies
in 2 l cDNA obtained from a 50 l reverse transcriptase
reaction of 800 ng RNA
RELATIVE NUMBER MEAN MEAN P VALUE
OF COPIES (PATIENTS) (CONTROLS)
hGR  41,887 56,025 0.02
hGR  69 42 0.02
hGR P 8,889 11,922 0.09
hGR / hGR P 4.7 5.1 0.19
hGR / hGR  679 1,523 0.001
Total 50,844 67,752 0.02
hGR = human glucocorticoid receptor.
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relation between the hGR  and hGR P variants and the
serum activity of alkaline phosphatase, a routinely used
marker of disease activity in PBC and PSC. A correlation
between the receptor variants and fatigue was not found.
An association between increased levels of hGR  mRNA
and glucocorticoid resistance in asthma and ulcerative
colitis has been reported previously.14-17,20,21 In addition,
increased expression of this variant has been observed in
patients with hormone resistant nephrotic syndrome,
chronic lymphatic leukaemia and nasal polyps.32-35 Several
in vitro studies have shown that expression of hGR  can
be induced by the inflammatory cytokines Il-2, Il-4, Il-7,
Il-8 and TNF-.20-22 The increase of hGR  as a result of
cytokine exposure correlated with a decrease in gluco-
corticoid sensitivity in one of these studies.22 Further, the
frequency of a polymorphism associated with increased
stability of hGR  mRNA was increased in patients with
rheumatoid arthritis. The authors suggested that this
could be a cause of glucocorticoid resistance, which is a
common problem in this condition.36 However, despite a
significant number of studies reporting it, controversy
regarding the negative effects of this variant does still
exist, since several other in vivo and in vitro studies found
no effects of the hGR  variant, and the mechanisms
responsible for the dominant negative effect are largely
unknown.13,19,37-39 In the present study, levels of hGR 
mRNA were much lower than those of the other variants.
This does not exclude a role for this variant in causing
glucocorticoid resistance, since similar results have been
obtained in previous studies reporting quantitative hGR
mRNA levels, and it might have several explanations.14,35
First, mRNA does not necessarily correspond with protein
levels, and hGR  protein levels could better reflect the
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Table 3
Correlation between hGR mRNA and fatigue
HGR  HGR  HGR P TOTAL
coeff. P coeff. P coeff. P coeff. p
VAS -0.089 0.81 -0.29 0.43 0.12 0.75 -0.02 0.96
FFSS physical domain -0.26 0.47 -0.30 0.40 -0.07 0.86 -0.20 0.58
FFSS cognitive domain -0.93 0.80 0.21 0.55 0.14 0.71 -0.01 0.97
FFSS social domain -0.26 0.47 -0.10 0.79 0.15 0.69 -0.12 0.74
Coeff. = coefficient, hGR = human glucocorticoid receptor, VAS = visual analogue scale, FFSS = Fisk fatigue severity scale.
Table 4
Correlation between hGR mRNA and biochemical markers of disease activity and severity
HGR  HGR  HGR P TOTAL
coeff. P coeff. P coeff. P coeff. p
Total serum bilirubin -0.38 0.28 0.11 0.76 -0.063 0.86 -0.28 0.43
Alkaline phosphatase -0.65 0.041 -0.28 0.44 -0.64 0.049 -0.68 0.03
Aspartate aminotransferase -0.39 0.27 -0.20 0.58 -0.61 0.063 -0.48 0.16
Immunoglobulin M -0.10 0.78 0.11 0.76 -0.31 0.39 -0.18 0.62
hGR = human glucocorticoid receptor, coeff. = coefficient.
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Figure 1
Relation between total GR mRNA and serum activity of
alkaline phosphatase 
10Log(alkaline phosphatase) is shown on the X-axis and
total hGR mRNA is shown on the Y-axis.
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mechanism leading to glucocorticoid resistance, although
a previous paper reported very low or undetectable hGR 
protein levels in the presence of similar mRNA levels as
in the present study.19 Second, in the present study blood
samples were studied, whereas the disease occurs primarily
in the liver. Thus, studying blood samples may have diluted
the hypothetically higher intrahepatic hGR  levels.
Third, significantly lower levels of hGR  compared with
total hGR levels might be needed to induce glucocorticoid
resistance, although the mechanism responsible for this
presumed dominant negative effect of the hGR  variant
is unclear.23
Thus, the increased levels of hGR  mRNA in patients in
the present study compared with healthy controls may
have been caused by the inflammatory nature of these
liver diseases, and it can be hypothesised that the modest
efficacy of glucocorticoid treatment in these diseases
could be caused by an increased expression of hGR .28,29
Another explanation for the increased hGR  mRNA
levels, in parallel to the hypothesis by Derijk et al. in
rheumatoid arthritis, is that patients with increased hGR
 expression are at increased risk of developing auto-
immune diseases due to resistance to endogenous gluco-
corticoids.36
An inverse correlation between the levels of hGR  and
hGR P, and therefore total hGR mRNA, and the serum
activity of alkaline phosphatase was found, whereas we
found no correlation with the other markers of disease
activity or severity. Such a relation with disease activity
has been reported previously in patients with systemic
lupus erythematosus, where glucocorticoid sensitivity
correlated with total hGR levels.40 In patients with
rheumatoid arthritis, hGR levels were decreased in
patients compared with controls.41,42 These studies suggest
that, in addition to hGR  expression, hGR  and hGR P
levels might also play a role in determining disease activity
and glucocorticoid resistance.
The most important limitation of the present study is its
small sample size, and therefore confirmation of the
results of the present study in a subsequent larger study
would be valuable. In addition, the present study design
does not allow conclusions with regard to the cause of
abnormalities in hGR expression.
In conclusion, we found increased expression of hGR 
mRNA in patients with cholestatic liver diseases as
compared with controls and an inverse relation between
the hGR  and hGR P mRNA and the serum activity of
alkaline phosphatase. This suggests that the glucocorticoid
receptor might be involved in the pathogenesis of these
diseases as well as in their relative glucocorticoid resistance.
Since we found no correlation with fatigue, it seems
unlikely that differential expression of hGR variants
plays a major role in the aetiology of this distressing
symptom of PBC and PSC.
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